Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001

Don Des Jarlais, Theresa Perlis, Kamyar Arasteh, Lucia V. Torian, Holly Hagan, Sara Beatrice, Lou Smith, Judith Wethers, Judith Milliken, Donna Mildvan, Stanley Yancovitz, Samuel R. Friedman

Research output: Contribution to journalArticle

Abstract

Objective: To assess trends in HIV, hepatitis C virus (HCV) and HIV/HCV infection among injecting drug users (IDU) from 1990 to 2001 in New York City. The 1990-2001 time period included a very large expansion of syringe exchange in New York City, from 250 000 to 3 000 000 syringes exchanged annually. Methods: Cross-sectional seroprevalence surveys of IDU entering drug abuse treatment in New York City, with sample sizes for HCV of 72 in 1990-1991 and 412 in 2000-2001. A structured risk behavior questionnaire was administered, and HIV and HCV testing were conducted. HCV testing was performed on de-linked stored serum samples. Results: Over the 1990-2001 period, HIV prevalence declined from 54 to 13%. HCV prevalence declined from 80 to 59% among HIV-seronegative individuals, and from 90 to 63% overall. The estimated HCV incidence in 2000-2001 among new injectors was 18 per 100 person-years at risk. Conclusions: The large-scale expansion of syringe exchange was temporally associated with large reductions in both HIV and HCV prevalence. The prevalence and incidence of HCV, however, still remain at high levels among IDU in New York City.

Original languageEnglish (US)
JournalAIDS
Volume19
Issue numberSUPPL. 3
StatePublished - Oct 2005

Fingerprint

Virus Diseases
Drug Users
Hepacivirus
HIV Infections
HIV
Syringes
Incidence
Seroepidemiologic Studies
Risk-Taking
Sample Size
Substance-Related Disorders
Cross-Sectional Studies
Serum

Keywords

  • Hepatitis C virus
  • HIV
  • Injecting drug users
  • Prevention

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. / Des Jarlais, Don; Perlis, Theresa; Arasteh, Kamyar; Torian, Lucia V.; Hagan, Holly; Beatrice, Sara; Smith, Lou; Wethers, Judith; Milliken, Judith; Mildvan, Donna; Yancovitz, Stanley; Friedman, Samuel R.

In: AIDS, Vol. 19, No. SUPPL. 3, 10.2005.

Research output: Contribution to journalArticle

Des Jarlais, D, Perlis, T, Arasteh, K, Torian, LV, Hagan, H, Beatrice, S, Smith, L, Wethers, J, Milliken, J, Mildvan, D, Yancovitz, S & Friedman, SR 2005, 'Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001', AIDS, vol. 19, no. SUPPL. 3.
Des Jarlais, Don ; Perlis, Theresa ; Arasteh, Kamyar ; Torian, Lucia V. ; Hagan, Holly ; Beatrice, Sara ; Smith, Lou ; Wethers, Judith ; Milliken, Judith ; Mildvan, Donna ; Yancovitz, Stanley ; Friedman, Samuel R. / Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. In: AIDS. 2005 ; Vol. 19, No. SUPPL. 3.
@article{245c9c84a3b64a209e848e0849585b10,
title = "Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001",
abstract = "Objective: To assess trends in HIV, hepatitis C virus (HCV) and HIV/HCV infection among injecting drug users (IDU) from 1990 to 2001 in New York City. The 1990-2001 time period included a very large expansion of syringe exchange in New York City, from 250 000 to 3 000 000 syringes exchanged annually. Methods: Cross-sectional seroprevalence surveys of IDU entering drug abuse treatment in New York City, with sample sizes for HCV of 72 in 1990-1991 and 412 in 2000-2001. A structured risk behavior questionnaire was administered, and HIV and HCV testing were conducted. HCV testing was performed on de-linked stored serum samples. Results: Over the 1990-2001 period, HIV prevalence declined from 54 to 13{\%}. HCV prevalence declined from 80 to 59{\%} among HIV-seronegative individuals, and from 90 to 63{\%} overall. The estimated HCV incidence in 2000-2001 among new injectors was 18 per 100 person-years at risk. Conclusions: The large-scale expansion of syringe exchange was temporally associated with large reductions in both HIV and HCV prevalence. The prevalence and incidence of HCV, however, still remain at high levels among IDU in New York City.",
keywords = "Hepatitis C virus, HIV, Injecting drug users, Prevention",
author = "{Des Jarlais}, Don and Theresa Perlis and Kamyar Arasteh and Torian, {Lucia V.} and Holly Hagan and Sara Beatrice and Lou Smith and Judith Wethers and Judith Milliken and Donna Mildvan and Stanley Yancovitz and Friedman, {Samuel R.}",
year = "2005",
month = "10",
language = "English (US)",
volume = "19",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001

AU - Des Jarlais, Don

AU - Perlis, Theresa

AU - Arasteh, Kamyar

AU - Torian, Lucia V.

AU - Hagan, Holly

AU - Beatrice, Sara

AU - Smith, Lou

AU - Wethers, Judith

AU - Milliken, Judith

AU - Mildvan, Donna

AU - Yancovitz, Stanley

AU - Friedman, Samuel R.

PY - 2005/10

Y1 - 2005/10

N2 - Objective: To assess trends in HIV, hepatitis C virus (HCV) and HIV/HCV infection among injecting drug users (IDU) from 1990 to 2001 in New York City. The 1990-2001 time period included a very large expansion of syringe exchange in New York City, from 250 000 to 3 000 000 syringes exchanged annually. Methods: Cross-sectional seroprevalence surveys of IDU entering drug abuse treatment in New York City, with sample sizes for HCV of 72 in 1990-1991 and 412 in 2000-2001. A structured risk behavior questionnaire was administered, and HIV and HCV testing were conducted. HCV testing was performed on de-linked stored serum samples. Results: Over the 1990-2001 period, HIV prevalence declined from 54 to 13%. HCV prevalence declined from 80 to 59% among HIV-seronegative individuals, and from 90 to 63% overall. The estimated HCV incidence in 2000-2001 among new injectors was 18 per 100 person-years at risk. Conclusions: The large-scale expansion of syringe exchange was temporally associated with large reductions in both HIV and HCV prevalence. The prevalence and incidence of HCV, however, still remain at high levels among IDU in New York City.

AB - Objective: To assess trends in HIV, hepatitis C virus (HCV) and HIV/HCV infection among injecting drug users (IDU) from 1990 to 2001 in New York City. The 1990-2001 time period included a very large expansion of syringe exchange in New York City, from 250 000 to 3 000 000 syringes exchanged annually. Methods: Cross-sectional seroprevalence surveys of IDU entering drug abuse treatment in New York City, with sample sizes for HCV of 72 in 1990-1991 and 412 in 2000-2001. A structured risk behavior questionnaire was administered, and HIV and HCV testing were conducted. HCV testing was performed on de-linked stored serum samples. Results: Over the 1990-2001 period, HIV prevalence declined from 54 to 13%. HCV prevalence declined from 80 to 59% among HIV-seronegative individuals, and from 90 to 63% overall. The estimated HCV incidence in 2000-2001 among new injectors was 18 per 100 person-years at risk. Conclusions: The large-scale expansion of syringe exchange was temporally associated with large reductions in both HIV and HCV prevalence. The prevalence and incidence of HCV, however, still remain at high levels among IDU in New York City.

KW - Hepatitis C virus

KW - HIV

KW - Injecting drug users

KW - Prevention

UR - http://www.scopus.com/inward/record.url?scp=27944459243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27944459243&partnerID=8YFLogxK

M3 - Article

VL - 19

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - SUPPL. 3

ER -